Supernus Announces FDA Approval of Qelbree for the Treatment of ADHD in Adults
First novel, nonstimulant option for adults with ADHD in 20 years
ADHD affects an estimated 10 million adults in the U.S.
ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: ADHD | Drugs & Pharmacology